Objective: To describe a temporal association between COVID-19 vaccine administration and multiple sclerosis (MS) relapses. Methods: This case series study was collected in four MS Centres in Central Italy, using data from 16 MS patients who received COVID-19 vaccination and presented both clinically and radiologically confirmed relapses between March and June 2021. We collected patients’ relevant medical history, including demographics, MS clinical course, disease-modifying treatment (DMT) received (if applicable), and data from MRI scans obtained after the COVID-19 vaccination. Results: Three out of 16 patients received a diagnosis of MS with a first episode occurring after COVID-19 vaccination; 13 had already a diagnosis of MS and, among them, 9 were on treatment with DMTs. Ten patients received BNT162b2/Pfizer-BioNTech, 2 patients mRNA-1273/Moderna, and 4 patients ChAdOx1 nCoV-19/AstraZeneca. All MS relapses occurred from 3 days to 3 weeks after receiving the first dose of the COVID-19 vaccination or the booster. All patients had evidence of radiological activity on MRI. Discussion: Clinical and radiological findings in these cohort of MS patients confirmed disease re/activation and suggested a temporal association between disease activity and COVID-19 vaccination. The nature of this temporal association, whether causative or incidental, remains to be established.
【저자키워드】 COVID-19 vaccine, SARS-CoV2 infection, adverse event, lesions, multiple sclerosis relapse, MRI activity, 【초록키워드】 COVID-19, Treatment, multiple sclerosis, Diagnosis, Italy, MRI, Cohort, Clinical course, COVID-19 vaccination, clinical, Patient, disease, ChAdOx1, booster, association, Disease activity, Evidence, administration, demographics, first dose, radiological finding, radiological, collected, occurred, clinically, receiving, was collected, case sery, suggested, 【제목키워드】 clinical, Relapse, Multiple, sclerosis, Against, Sery,